Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427058 | 1.00 | IDO1 (0.47) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL3711395 | 0.86 | ALDH1A1 (0.44) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL18488224 | 0.84 | ALDH1A1 (0.43) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL23430126 | 0.83 | MBTD1 (0.38) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL6204786 | 0.83 | IDO1 (0.46) | IDO1TDO2ALDH1A1MAPK1GBA1 | |
| SCHEMBL28920974 | 0.81 | IDO1 (0.44) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL6204787 | 0.81 | IDO1 (0.44) | IDO1TDO2ALDH1A1MAPK1C1S | |
| SCHEMBL4209186 | 0.81 | IDO1 (0.48) | IDO1TDO2ALDH1A1MAPK1MAOA | |
| SCHEMBL17922061 | 0.81 | IDO1 (0.44) | IDO1TDO2ALDH1A1MAPK1MBTD1 | |
| SCHEMBL1538725 | 0.81 | PGK1 (0.48) | ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-01 | — | — | US | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-6344558-B1 | ANALGESICS | GRUENTHAL GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | GRUENENTHAL GMBH | 2002-01-24 | — | — | US | disclosed |
| US-6248737-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2001-06-19 | — | — | US | disclosed |
| WO-2001010816-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2001-02-15 | — | — | WO | disclosed |
| EP-1069106-A2 | Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity | Grünenthal GmbH (DE) | 2001-01-17 | — | — | EP | disclosed |
| EP-0983995-A2 | Pharmaceutically-active dimethyl-(3-aryl-but-3-enyl)-amine compounds | Grünenthal GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5811582-A | ANALGESICS | GRUENENTHAL GMBH (DE) | 1998-09-22 | — | — | US | disclosed |
| EP-0693475-B1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | GRUENENTHAL GMBH (DE) | 1998-02-11 | — | — | EP | disclosed |
| EP-0799819-A1 | Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity | Grünenthal GmbH (DE) | 1997-10-08 | — | — | EP | disclosed |
| EP-0693475-A1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | Grünenthal GmbH (DE) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | OPRM1, OPRK1, OPRD1 | IDO1 1145/4885TDO2 2921/4885ALDH1A1 135/4885 |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | IDO1 3105/4885TDO2 2898/4885ALDH1A1 2437/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | IDO1 2046/4885TDO2 2553/4885ALDH1A1 4336/4885 |
| US-12421191-B2 | 3-hydroxyoxindole derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | IDO1 576/4885TDO2 617/4885ALDH1A1 4326/4885 |
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | IDO1 3105/4885TDO2 2898/4885ALDH1A1 2437/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | IDO1 441/4885TDO2 1026/4885ALDH1A1 472/4885 |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | PTGES, PTGS1, PTGIS | IDO1 564/4885TDO2 1084/4885ALDH1A1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.